Taysha Gene Therapies, Inc. TSHA Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s stock issuance proceeds?
- Taysha Gene Therapies, Inc. (TSHA) reported stock issuance proceeds of $516K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s stock issuance proceeds changed year-over-year?
- Taysha Gene Therapies, Inc.'s stock issuance proceeds increased by 588.0% year-over-year, from $75K to $516K.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.